Literature DB >> 24426802

Influenza vaccine recommendations for children and youth for the 2013/2014 season.

Dorothy L Moore.   

Abstract

Recommendations from the National Advisory Committee on Immunization concerning indications for the routine influenza vaccination of children and their close contacts have not changed from those of 2012/2013. Intranasal, live attenuated influenza vaccine (LAIV) is preferred over trivalent inactivated influenza vaccines (TIV) for healthy children and youth. There is insufficient evidence to recommend LAIV over TIV in children with chronic health conditions; either may be used unless there are specific contraindications. TIV may be used in persons with egg allergy; LAIV has not yet been evaluated in this population and is not recommended at this time.

Entities:  

Keywords:  Children; Influenza vaccine; LAIV; TIV

Year:  2013        PMID: 24426802      PMCID: PMC3887090          DOI: 10.1093/pch/18.8.e51

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  2 in total

1.  Influenza vaccine recommendations for children and youth for the 2012/2013 season.

Authors:  Dorothy L Moore
Journal:  Paediatr Child Health       Date:  2012-10       Impact factor: 2.253

2.  Use of influenza vaccines in children with an egg allergy.

Authors:  Charles Ps Hui; Noni E Macdonald
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

  2 in total
  2 in total

1.  Vaccine recommendations for children and youth for the 2014/2015 influenza season.

Authors:  Dorothy L Moore
Journal:  Paediatr Child Health       Date:  2014-10       Impact factor: 2.253

2.  Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Min-Kyoung Cho; Young-Man Kwon; Jong Seok Lee; Richard K Plemper; Sang-Moo Kang
Journal:  Virology       Date:  2014-12-30       Impact factor: 3.616

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.